化合物 Rimeporide|T5319|TargetMol

Rimeporide
187870-78-6

￥631 1mg 起订

￥918 2mg 起订

￥1490 5mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 Rimeporide

英文名称：: Rimeporide

CAS号：: 187870-78-6

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 97.66%

产品类别：: 抑制剂

货号：: T5319

Product Introduction

Bioactivity

名称	Rimeporide
描述	Rimeporide (EMD-87580) (EMD-87580) is a potent and selective Sodium hydrogen exchange 1 (NHE-1) inhibitor.
细胞实验	To induce hypertrophy, myocytes were treated for 10 min or 24 h as appropriate and noted under Results with 10 μM phenylephrine in the absence or presence of the following agents: the NHE-1 inhibitor EMD87580 (5 μM) or cariporide (5 μM), the JNK1/2 inhibitor SP600125, the p38 inhibitor SB203580, the ERK1/2 inhibitor PD98059 (all at 10 μM), and the reverse mode Na+-Ca2+ exchange inhibitor KB-R7943 or SN-6 (both at 10 μM). All drugs were added 30 min before the addition of phenylephrine [1].
动物实验	Two groups were studied. The treatment group (n = 5) received EMD 87580 at a dose of 5 mg/kg IV bolus 5 min before aortic cross-clamping and 10 mol/L EMD 87580 in the cardioplegic solution. The control group (n = 9) received the same volume of saline vehicle. Systemic pretreatment was used to ensure drug availability during the ischemic period prior to CPA. Direct infusion via cardioplegia ensures drug delivery at the time of ischemia (CPA), and it decreases the variability of drug delivery that may occur during the hemodilution with CPB initiation. Incorporation into the cardioplegia also minimizes the potential variable of drug/extracorporeal circuit interactions. Using this dosing regimen, the plasma concentration of EMD 87580 was in the 2,500 to 3,000 ng/mL range at 10 min after CPB. This concentration has been shown to be effective at Na+/H+ exchanger inhibition in vitro [2].
体外活性	使用10 μM 酚麻黄碱处理24小时显著增加了细胞表面积至控制值的129.6±3.1%。酚麻黄碱的肥大效应被5 μM EMD87580 [1] 完全抑制。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 15 mg/mL (50 mM)
关键字	Inhibitor \| EMD87580 \| Sodium-hydrogen Exchanger \| EMD 87580 \| Sodium/hydrogen Exchanger \| inhibit \| Na+/H+ Exchanger (NHE) \| Rimeporide
相关产品	Lidocaine hydrochloride \| Benzocaine \| Lidocaine \| Mebeverine hydrochloride \| Valproic Acid \| Nefopam hydrochloride \| Amitriptyline hydrochloride \| L-Aspartic aicd sodium \| Lidocaine Hydrochloride hydrate \| Riluzole \| Butamben \| Phenytoin sodium
相关库	抑制剂库 \| 神经保护化合物库 \| 经典已知活性库 \| 已知活性化合物库 \| 离子通道库 \| 膜蛋白靶向化合物库 \| 药物功能重定位化合物库 \| 疼痛相关化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

EMD-87580|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务